Vicky Wu

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 4 papers. Top paper: “Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL”.

Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL

Blood(2022)10.1182/blood.2021014497

N/A

0DataRank · unranked

54 citations

Nicolas Gazeau, Alexandre V. Hirayama, Joshua A. Hill, Vicky Wu, Aisling Cearley +17 more

Long-term efficacy and safety of pembrolizumab with R-CHOP as first-line therapy for DLBCL.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.7561

N/A

0DataRank · unranked

1 citations

Jonathan R. Fromm, Min Fang, Brian G. Till, Mazyar Shadman, Andrew J. Cowan +11 more

Pediatric oncologist referral practices for CAR T-cell therapy: A mixed methods study.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.10026

N/A

0DataRank · unranked

1 citations

Devan M. Duenas, Jenna Voutsinas, Vicky Wu, Adam J. Lamble, Benjamin S. Wilfond +4 more

Long term outcomes in patients with recurrent/metastatic (R/M) salivary gland cancer (SGC) treated with immune checkpoint inhibitors (ICI).

Journal of Clinical Oncology(2024)10.1200/jco.2024.42.16_suppl.e18063

N/A

0DataRank · unranked

1 citations

Vicky Wu, Kevin Ng, Jenna Voutsinas, Ariana Dumenigo‐Jimenez, Jonathan R. Fromm +15 more